# Shiga Microalbuminuria Reduction Trial-2

Study · id `cardio:ct-nct01461499` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01461499](<https://clinicaltrials.gov/study/NCT01461499>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01461499

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 237 participants.

## Technical summary

Registry record NCT01461499. Randomized; no masking; primary purpose treatment. Start 2011-10 (registry gives no type); primary completion 2014-08 (actual). Results posted on 2018-02-19.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 237 participants (enrolled count; ClinicalTrials.gov record NCT01461499, source copy `cardio:ctgov-nct01461499-2018-02-19`, retrieved 2026-10-26)
- Start date: 2011-10 (registry gives no type) (ClinicalTrials.gov record NCT01461499, source copy `cardio:ctgov-nct01461499-2018-02-19`, retrieved 2026-10-26)
- Primary completion: 2014-08 (actual) (ClinicalTrials.gov record NCT01461499, source copy `cardio:ctgov-nct01461499-2018-02-19`, retrieved 2026-10-26)
- Completion: 2014-12 (actual) (ClinicalTrials.gov record NCT01461499, source copy `cardio:ctgov-nct01461499-2018-02-19`, retrieved 2026-10-26)
- Results first posted: 2018-02-19 (ClinicalTrials.gov record NCT01461499, source copy `cardio:ctgov-nct01461499-2018-02-19`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT01461499, source copy `cardio:ctgov-nct01461499-2018-02-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01461499-2018-02-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: Shiga Microalbuminuria Reduction Trial-2
- Condition: Type 2 Diabetes Mellitus
- Condition: Hypertension
- Intervention (Drug): Aliskiren
- Intervention (Drug): any angiotensin receptor blockers
- Lead sponsor: Shiga University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)

## Provenance

Content hash: aad6caa7c4a6ea70477db369a1da4a27e3731a8b38ebef92597279361ace76c0
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
